KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Change in Accured Expenses: 2018-2025

Historic Change in Accured Expenses for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $9.5 million.

  • Castle Biosciences' Change in Accured Expenses rose 47.43% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 28.82%. This contributed to the annual value of $3.6 million for FY2024, which is 21.30% down from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Change in Accured Expenses is $9.5 million, which was up 33.28% from $7.1 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Change in Accured Expenses registered a high of $9.5 million during Q3 2025, and its lowest value of -$14.7 million during Q1 2025.
  • Moreover, its 3-year median value for Change in Accured Expenses was $5.1 million (2023), whereas its average is $918,091.
  • Examining YoY changes over the last 5 years, Castle Biosciences' Change in Accured Expenses showed a top increase of 137.80% in 2022 and a maximum decrease of 77.40% in 2022.
  • Quarterly analysis of 5 years shows Castle Biosciences' Change in Accured Expenses stood at $3.2 million in 2021, then soared by 51.00% to $4.8 million in 2022, then skyrocketed by 35.52% to $6.5 million in 2023, then fell by 25.34% to $4.9 million in 2024, then soared by 47.43% to $9.5 million in 2025.
  • Its last three reported values are $9.5 million in Q3 2025, $7.1 million for Q2 2025, and -$14.7 million during Q1 2025.